Stockreport

Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806
PDF Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020 WARMINSTER, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: [Read more]